Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has been given an average recommendation of “Hold” by the five analysts that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $3.33.

A number of analysts have weighed in on the stock. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com began coverage on shares of Syros Pharmaceuticals in a report on Monday, February 17th. They issued a “sell” rating on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th.

Syros Pharmaceuticals Trading Down 0.9 %

NASDAQ SYRS opened at $0.17 on Friday. The company has a 50 day moving average of $0.20 and a 200-day moving average of $1.13. The company has a market cap of $4.68 million, a price-to-earnings ratio of -0.06 and a beta of 1.29. Syros Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $7.96.

Institutional Investors Weigh In On Syros Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $34,000. Two Sigma Securities LLC bought a new stake in shares of Syros Pharmaceuticals during the fourth quarter worth about $25,000. Finally, Exome Asset Management LLC increased its position in shares of Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares in the last quarter. 91.47% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.